Welcome to
KaNDy
Therapeutics
Therapeutics
Developing a breakthrough non-hormonal treatment for multiple symptoms of the menopause including hot flashes and night time awakening
A unique approach
Progressing our unique once daily dual mechanism neurokinin antagonist, NT-814, as a potential breakthrough treatment for multiple symptoms of the menopause. NT-814 has successfully completed a Phase 2a proof of concept study that demonstrated its potential to rapidly and profoundly reduce two key symptoms of the menopause: hot flashes and night time awakening. Preparations are underway for a multi-country Phase 2b study with NT-814 in this anchor Women’s Health indication, starting in Q4 2018.
Latest News
Contact Us
For general, media or partnership enquiries, get in touch with us:
